THE EMERGENCE AND DEVELOPMENT OF PHARMACEUTICAL DEONTOLOGY: COUNTERFEIT MEDICINES: A GLOBAL PUBLIC HEALTH THREAT

Authors

  • Yadgarova Sitora Qahramonovna Lecturer in Pharmaceutical Deontology Department of General Subjects Asia International University Bukhara, Uzbekistan

DOI:

https://doi.org/10.55640/

Keywords:

Counterfeit medicines, falsified drugs, pharmaceutical quality, public health, drug regulation, supply chain, patient safety, antimicrobial resistance, global health

Abstract

Counterfeit medicines represent a significant and growing challenge to global healthcare systems. These falsified pharmaceutical products may contain incorrect ingredients, improper dosages, or harmful substances, posing serious risks to patient safety. This article explores the scope of counterfeit medicines, their impact on public health, contributing factors, and strategies for prevention and control, supported by a review of relevant literature.

 

Downloads

Download data is not yet available.

References

1.Newton, P. N., et al. (2006). Counterfeit anti-infective drugs. The Lancet Infectious Diseases.

2.Nayyar, G. M. L., et al. (2012). Poor-quality antimalarial drugs in Africa and Southeast Asia. The Lancet Infectious Diseases.

3.World Health Organization (2017). A study on the public health and socioeconomic impact of substandard and falsified medical products.

4.Mackey, T. K., & Liang, B. A. (2011). The global counterfeit drug trade: patient safety and public health risks. Journal of Pharmaceutical Sciences.

5.The Lancet Global Health (various articles on antimicrobial resistance and counterfeit drugs).

Downloads

Published

2026-04-08

Issue

Vol. 5 No. 4 (2026): Journal of Multidisciplinary Sciences and Innovations

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

How to Cite

THE EMERGENCE AND DEVELOPMENT OF PHARMACEUTICAL DEONTOLOGY: COUNTERFEIT MEDICINES: A GLOBAL PUBLIC HEALTH THREAT. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(4), 580-581. https://doi.org/10.55640/

Similar Articles

21-30 of 2091

You may also start an advanced similarity search for this article.